scholarly journals PO-0143 Improving Time To Diagnosis In Children Referred Locally With Suspected Inflammatory Bowel Disease Within A Managed Clinical Network - A Single Centre, Secondary Care Experience

2014 ◽  
Vol 99 (Suppl 2) ◽  
pp. A294.2-A294
Author(s):  
M Thorpe ◽  
V Rodulson ◽  
C Harbinson ◽  
C Spray ◽  
S Sandmann
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Secondary Care ◽  
Single Centre ◽  
Care Experience ◽  
Clinical Network ◽  
Time To Diagnosis ◽  
Inflammatory Bowel

Inflammatory bowel disease in central India: a single centre experience over five years

2012 ◽  
Vol 42 (4) ◽  
pp. 198-199 ◽  
Author(s):  
Ajay K Jain ◽  
Shohini Sircar ◽  
Mayank Jain ◽  
Sagar Adkar ◽  
Chandrashekhar Waghmare
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Central India ◽  
Single Centre ◽  
Single Centre Experience ◽  
Inflammatory Bowel

scholarly journals P664 The impact of vedolizumab on extra-intestinal manifestations in inflammatory bowel disease patients: A real-life experience of a single-centre cohort

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S546-S547
Author(s):  
M TRUYENS ◽  
J Geldof ◽  
G Dewitte ◽  
E Glorieus ◽  
G Varkas ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Disease Activity ◽  
Bowel Disease ◽  
Life Experience ◽  
Real Life ◽  
Intestinal Disease ◽  
Single Centre ◽  
Clinical Evolution ◽  
Inflammatory Bowel ◽  
The Impact

Abstract Background Vedolizumab (VDZ), a gut-specific anti-integrin, is approved as a treatment for moderate to severe Crohn’s disease (CD) and ulcerative colitis (UC). Extra-intestinal manifestations (EIMs) are frequently associated with inflammatory bowel disease (IBD). However, the effect of VDZ on EIMs remains unknown. The aim of the current study was to describe the prevalence of EIMs in IBD patients at VDZ initiation, the evolution during continued treatment as well as the occurrence of new EIMs. Methods A single-centre study was performed in IBD patients who were started on VDZ between May 2010 and February 2019. Retrospectively, the physician-reported EIMs and intestinal disease activity (clinical and endoscopic) were assessed at baseline, 6 months and 1 year after the start of VDZ. Results The cohort consisted of 134 patients, including 77 CD patients, 56 UC patients and 1 patient with unclassified IBD. At VDZ initiation EIMs were assessed in 127 patients and 17.3% had ≥ 1 EIM: 9 hepatic EIMs (2 patients with toxic hepatitis, 2 with autoimmune hepatitis and 5 with PSC), 7 arthropathies (6 patients with axial spondyloarthropathy and 1 with peripheral arthritis), 3 non-further specified axial or peripheral arthralgias and 3 cutaneous EIMs (urticaria, psoriasis and erythema nodosum). Clinical evolution of the EIMs is reported in Table 1, assessment of intestinal disease activity in Table 2. During follow-up, 23 new EIMs were seen, mainly arthralgia, which was often transient. VDZ was stopped in 39/130 (30%) patients due to active intestinal disease in 32 patients, patients’ choice (n = 1) or because of deep disease remission (n = 1). In five patients, VDZ was stopped because of insufficient control of EIM. Conclusion A good clinical intestinal response was observed. However, the clinical evolution of EIMs appears unaffected by the use of VDZ in our cohort. Prospective data are needed to confirm these results.

PWE-030 Sigmoidoscopy both delays time to diagnosis and has poor diagnostic utility for paediatric-onset inflammatory bowel disease

Gut ◽  
2010 ◽  
Vol 59 (Suppl 1) ◽  
pp. A96.2-A96
Author(s):  
R J Dart ◽  
R K Russell ◽  
J R Read ◽  
P Rogers ◽  
P M Gillett ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Diagnostic Utility ◽  
Time To Diagnosis ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document